What Is Primary Sclerosing Cholangitis (PSC)?

Primary sclerosing cholangitis, usually called PSC, is a chronic liver disease in which the bile ducts inside and outside the liver become inflamed and progressively scarred, eventually narrowing or closing off entirely. There is no approved drug that slows or stops it, and for people whose liver function deteriorates far enough, transplantation remains the only definitive treatment. PSC is rare, but its tight connection to inflammatory bowel disease, its elevated cancer risk, and the absence of effective medication make it one of the more vexing conditions in hepatology.

What Happens Inside the Bile Ducts

Bile ducts are the plumbing that carries bile from the liver to the small intestine, where bile helps digest fats. In PSC, immune-driven inflammation damages the cells lining those ducts, called cholangiocytes. Over time, scar tissue wraps concentrically around the duct walls in a pattern pathologists describe as “onion-skin fibrosis,” a hallmark of the disease.¹ The scarring creates strictures, segments where the duct narrows so much that bile backs up. When bile cannot flow freely, it damages liver cells, drives more inflammation, and gradually leads to cirrhosis.

Cholangiocytes are not passive bystanders. They actively modify bile composition, respond to injury signals, and communicate with immune cells. Their dysfunction sits at the center of PSC and a broader family of bile-duct diseases that researchers call cholangiopathies.² Understanding why cholangiocytes behave abnormally in PSC is an active area of research, but no single trigger has been pinpointed.

How Common PSC Is and Who Gets It

PSC is rare by any measure, though reported prevalence varies by population. A U.S. community-based study in Olmsted County, Minnesota, found the age-adjusted incidence to be about 1.25 per 100,000 person-years in men and 0.54 in women, with an overall prevalence around 21 per 100,000 men and 6 per 100,000 women.³ A study in a more ethnically diverse U.S. population found a lower point prevalence of about 4 per 100,000, with the sex difference narrowing considerably.⁴ The mean age at diagnosis in that cohort was 44 years, though cases ranged from age 11 to 81. Taken together, the numbers confirm that PSC is uncommon, occurs more often in men, and is typically diagnosed in middle adulthood.

Symptoms and How the Disease Feels

Many people with PSC are diagnosed before they ever feel sick, often after routine blood work reveals elevated liver enzymes. When symptoms do appear, fatigue and itching are the most prominent. A multicenter prospective study found that roughly half of PSC patients reported pruritus (itching), with about a quarter experiencing moderate-to-severe itch.⁵ Worse itching correlated with younger age and markers of more advanced liver disease, including higher liver stiffness on elastography and higher bilirubin levels.

Because the itching in PSC is driven by bile acid accumulation rather than histamine, conventional antihistamines are generally ineffective. American guidelines recommend starting with bile acid-binding resins, with rifampin, sertraline, or naltrexone as second-line options. European guidelines instead favor bezafibrate as a first step, based on emerging evidence for fibrates in cholestatic itch.⁶ In practice, registry data show that bile acid-binding resins were used in fewer than half of patients with moderate or severe itch, and antihistamines were prescribed almost as often despite the lack of evidence that they help. If you or someone you know has PSC-related itch that is not responding to over-the-counter antihistamines, that is expected rather than unusual, and a hepatologist can try therapies better suited to cholestatic itch.

Other symptoms that may appear over time include right-upper-abdominal discomfort, jaundice, fevers from bacterial cholangitis (infection of the bile ducts), and eventually signs of cirrhosis such as fluid retention and muscle wasting.

The Deep Link Between PSC and Inflammatory Bowel Disease

The relationship between PSC and inflammatory bowel disease is one of the most striking associations in medicine. Somewhere around 60 to 80 percent of people with PSC also have IBD, most commonly ulcerative colitis. But the colitis seen alongside PSC is not ordinary. It tends to involve the entire colon (pancolitis), often spares the rectum, and may include backwash ileitis, all features that differ from typical ulcerative colitis.⁷ One study found pancolitis in 94 percent of PSC patients with ulcerative colitis and colonic involvement in 96 percent of those with Crohn’s disease.⁸

Paradoxically, despite widespread colonic inflammation, many PSC-IBD patients have mild gut symptoms or none at all, which can delay the IBD diagnosis.⁹ This is why most hepatologists recommend that anyone newly diagnosed with PSC undergo colonoscopy even without bowel complaints.

What connects the gut and the liver in PSC appears to involve multiple pathways. Researchers have framed it as a triad of gut dysbiosis, altered bile acid metabolism, and immune-mediated biliary injury.¹⁰ Studies of the gut microbiome in PSC consistently show lower bacterial diversity compared to healthy individuals, enrichment of certain bacteria like Veillonella, Enterococcus, and Streptococcus, and depletion of bacteria that produce short-chain fatty acids, which help maintain a healthy gut lining.¹¹ Whether these microbial shifts cause PSC, result from it, or simply co-occur remains one of the open questions in the field. Research into T cells has shown that immune cells originally activated in the gut can travel to the liver, potentially driving inflammation there, though this trafficking turns out not to be unique to PSC and occurs in other chronic liver diseases as well.¹²

Genetics and Immune Roots

PSC is not a straightforward genetic disease, but it has a clear genetic component. The strongest associations point to the HLA region on chromosome 6, a stretch of DNA central to how the immune system recognizes threats. A genome-wide association study found that variants near HLA-B on chromosome 6p21 carried an odds ratio close to 5 for PSC risk.¹³ The presence of these HLA associations, along with autoantibodies found in the blood of many PSC patients, strongly implies that immune-mediated mechanisms drive the disease.¹⁴

Beyond HLA, extended genetic studies have identified over a dozen additional risk loci, including regions on chromosomes 1p36 and 19q13. The chromosome 19 locus involves the FUT2 gene, which influences susceptibility to certain infections, hinting at a possible environmental trigger interacting with genetic predisposition.¹⁵ Several of the susceptibility loci overlap with those for ulcerative colitis, which may partly explain why the two diseases travel together so often.

Environmental Observations

A few environmental associations have emerged in epidemiological studies, though none has led to a proven preventive strategy. A meta-analysis of seven case-control studies found that current smokers had roughly a third the risk of PSC compared to nonsmokers, and former smokers about half the risk.¹⁶ A similar inverse relationship holds for ulcerative colitis, and since most PSC patients have UC, disentangling the two is tricky. To be clear, nobody recommends smoking as protection. The finding is interesting biologically but clinically useless.

Coffee drinking also turns up as inversely associated with PSC. A Norwegian study found that a lower proportion of PSC patients were daily coffee drinkers compared to controls, and that daily coffee consumption at age 18 was independently and negatively associated with PSC risk.¹⁷ Dietary surveys have also noted that PSC patients were less likely to eat fish, though more likely to eat well-done red meat.¹⁸ These are associations, not causes. They suggest environmental factors play some role but do not yet point to actionable lifestyle changes.

How PSC Is Diagnosed

The cornerstone of PSC diagnosis is imaging the bile ducts. Magnetic resonance cholangiopancreatography, or MRCP, has largely replaced the older and more invasive endoscopic retrograde cholangiopancreatography (ERCP) for diagnostic purposes. A meta-analysis found MRCP had a sensitivity of 86 percent and a specificity of 94 percent for detecting PSC, meaning it catches most cases and rarely produces false positives.¹⁹ A head-to-head comparison found that MRCP and ERCP had similar overall diagnostic accuracy, with MRCP sensitivity around 80 percent and ERCP sensitivity around 89 percent.²⁰ Since ERCP carries procedural risks, including pancreatitis, MRCP is now the first-line imaging choice when PSC is suspected.

Beyond diagnosis, clinicians need to estimate how the disease will progress. Liver stiffness measured by transient elastography (a specialized ultrasound technique) has shown promise. A score above roughly 10 to 11 kPa is associated with poorer survival and liver-related complications.²¹ When liver stiffness is combined with MRI-based scoring, patients can be stratified into low-, medium-, and high-risk groups; five-year rates of adverse outcomes in those groups have been reported as 8 percent, 16 percent, and 38 percent, respectively.²²

Cancer Risk

One of the most concerning aspects of PSC is the elevated risk of several cancers. Cholangiocarcinoma, or bile duct cancer, carries an estimated lifetime risk of 10 to 15 percent in PSC patients. About a third of these cancers are found within the first year of PSC diagnosis, suggesting they may have been present before the PSC was recognized. After that, the rate runs at roughly 1.5 percent per year.²³ Because cholangiocarcinoma can be difficult to detect early and has poor outcomes when caught late, many specialists recommend surveillance with MRI/MRCP and the blood marker CA 19-9 every six months, even though official U.S. guidelines have not formally endorsed routine screening.

Colorectal cancer is the other major concern, particularly in patients who have both PSC and ulcerative colitis. A large population-based study found that PSC patients had roughly 7.5 times the risk of colorectal cancer compared to matched controls.²⁴ A meta-analysis looking specifically at patients with both UC and PSC estimated that the odds of colorectal dysplasia or cancer were about four to five times higher than in UC patients without PSC.²⁵ Annual or biennial colonoscopy with extensive biopsies is widely recommended for PSC-IBD patients, starting from the time of PSC diagnosis regardless of how long they have had colitis.

Why No Drug Has Worked Yet

Ursodeoxycholic acid, or UDCA, is the drug most commonly associated with PSC, and its story is a cautionary tale about surrogate markers. At standard doses, UDCA improves liver-enzyme levels on blood tests, which initially generated optimism. But a randomized trial in the New England Journal of Medicine found no clinical benefit: the rate of treatment failure was essentially identical in the UDCA and placebo groups.²⁶ Worse, a trial of high-dose UDCA (28 to 30 mg/kg/day) was stopped early because the drug group had more than twice the risk of reaching a clinical endpoint like death or transplant listing compared to placebo, and serious adverse events were significantly more common.²⁷ A meta-analysis pooling the available trials confirmed the picture: neither standard-dose nor high-dose UDCA improved mortality, itching, fatigue, cholangiocarcinoma risk, or histological progression.²⁸

Despite these results, some centers still prescribe moderate-dose UDCA, partly because it improves blood-test numbers and partly because there is simply nothing else proven to offer. The lack of any approved pharmacological therapy remains the defining frustration of PSC management, and dozens of clinical trials are underway testing agents that target bile acid signaling, fibrosis, and the gut-liver immune axis.²⁹

Endoscopic Management of Dominant Strictures

When a single narrowed segment of a major bile duct causes most of the obstruction, it is called a dominant stricture. Endoscopic treatment can relieve symptoms, improve bile flow, and sometimes buy years of better liver function. Two main endoscopic approaches exist: balloon dilation, where a small balloon is inflated inside the stricture to widen it, and stent placement, where a tube is left in the duct to hold it open. A recent meta-analysis found that both methods achieved similar clinical efficacy at around 85 percent, but balloon dilation required far fewer procedures per patient (about 3 versus 6 or 7 for stenting) and had substantially fewer complications, including a lower rate of cholangitis.³⁰ Stenting may be reserved for severe strictures or cases where balloon dilation fails, and the higher bilirubin reduction seen with stents suggests they are often used in more advanced disease.

Liver Transplantation and the Problem of Recurrence

For people with end-stage PSC, liver transplantation is life-saving and generally associated with good long-term survival. However, PSC can come back in the new liver. An analysis of the European Liver Transplant Registry found recurrent PSC in about 17 percent of patients after a median follow-up of five years, with recurrence significantly reducing graft and patient survival.³¹ A single-center study with longer follow-up reported even higher recurrence: 40 percent of patients over a median of 30 months, with the cumulative risk climbing above 45 percent by six years.³² Active inflammatory bowel disease after transplant was identified as an independent risk factor for recurrence, reinforcing the idea that whatever drives PSC involves immune processes that a new liver alone does not extinguish.

Small-Duct PSC

Not all PSC looks the same on imaging. About 5 to 6 percent of patients have a variant called small-duct PSC, where liver biopsies show the characteristic inflammation and fibrosis of PSC but the larger bile ducts appear normal on cholangiography.³³ This matters because the prognosis is significantly better. A study following patients for decades found that transplant-free survival was substantially longer in small-duct PSC than in classic large-duct PSC, and none of the small-duct patients developed cholangiocarcinoma, compared with about 11 percent in the large-duct group.³⁴

The catch is that about a quarter of small-duct PSC patients eventually progress to large-duct disease, at which point their risk profile worsens considerably. In one long-term cohort, 23 percent progressed over a median of roughly seven years.³⁵ Whether small-duct PSC represents a genuinely separate entity or simply an earlier stage of classic PSC remains debated, but from the patient’s perspective, the label carries meaningfully better news, at least at the time of diagnosis.

PSC in Children

PSC can appear in childhood, and when it does, it often looks different from the adult version. Up to half of pediatric PSC patients present with features that overlap with autoimmune hepatitis, a combination that can respond to immunosuppressive treatment in a way that adult PSC typically does not. Children also more commonly have a small-duct phenotype. Progression to cirrhosis and end-stage liver disease does occur in a significant proportion of pediatric patients, though the trajectories and transplant-free survival rates can differ from adults. The overlap with autoimmune hepatitis in children can complicate initial diagnosis, and recognition that PSC in a child may respond to immunosuppression, at least in part, is important for guiding early management.

Gallbladder Abnormalities

People with PSC also face an elevated rate of gallbladder problems, including polyps and gallbladder cancer. Many specialists recommend annual ultrasound surveillance of the gallbladder, and cholecystectomy (surgical removal) is often advised if a polyp is found, since distinguishing benign from malignant polyps is unreliable in this population. This is an area where PSC management diverges sharply from general practice, where small gallbladder polyps are often monitored conservatively. The heightened cancer vigilance that PSC demands extends across multiple organs, making coordinated care between hepatologists, gastroenterologists, and sometimes oncologists a practical reality for most patients living with this disease.